Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes

Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes.
A unfledged drug, the opening in its class, gives added blood sugar charge to mortals with type 2 diabetes who are already taking the glucose-lowering medication metformin. The callow agent, dapagliflozin, which also helped patients yield weight, is novel in that it does not work quickly on the body's insulin mechanisms, according to a study appearing in the June 26 come of The Lancet and slated for presentation at the annual conclave of the American Diabetes Association (ADA) in Orlando problems solutions. "It will indubitably be used as an add-on therapy," said study be conducive to author Clifford Bailey, a chemical pathologist and professor of clinical proficiency at Aston University in Birmingham, UK "If you don't undoubtedly get to target with the first therapy tried, this solicit would offer you an opportunity hopefully to maintain improved control".

Bailey, who could not forecast if or when the drug might get final approval from drug regulatory authorities, also spiky out that dapagliflozin is flexible, meaning it can be used with various other treatments and at more or less any put on in the disease. "It's a good add-on," agreed Dr Stanley Mirsky, confederate clinical professor of metabolic diseases at Mount Sinai Medical Center in New York City. "Is it a prodigy drug? No. It may amuse oneself a mignon role".

The study was funded by Bristol-Myers Squibb and AstraZeneca, which are developing dapagliflozin together. Dapagliflozin mechanism by stimulating the kidneys to exterminate more glucose from the body via urine. In this study of 534 matured patients with type 2 diabetes who were already taking metformin, the highest measure of dapagliflozin (10 milligrams daily) was associated with a 0,84 percent tapering off in HbA1c levels.

HbA1c is a measure of blood sugar supervise over time. Participants taking 5 mg of the dose saw a 0,70 percent decrease in HbA1c levels, while those taking 2.5 mg had a 0,67 percent decrease. In the placebo group, the shrink in HbA1c was 0,3 percent, the scrutinize found.